Insight Molecular Diagnostics (IMDX) Other Non-Current Assets (2016 - 2026)

Insight Molecular Diagnostics (IMDX) has 11 years of Other Non-Current Assets data on file, last reported at $1.2 million in Q1 2026.

• Quarterly Other Non-Current Assets fell 29.41% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 29.41% YoY) and the FY2025 annual result came in at $593000.0, down 14.18% from the prior year.
• Other Non-Current Assets grew to $1.2 million in Q1 2026 per IMDX's latest filing, from $593000.0 in the prior quarter.
• The five-year high for Other Non-Current Assets was $2.1 million in Q4 2022, with the low at $329000.0 in Q2 2023.
• Average Other Non-Current Assets over 5 years is $995529.4, with a median of $691000.0 recorded in 2024.
• Year-over-year, Other Non-Current Assets plunged 92.85% in 2022 and jumped 364.48% in 2023.
• Insight Molecular Diagnostics' Other Non-Current Assets stood at $2.1 million in 2022, then decreased by 19.85% to $1.7 million in 2023, then sank by 59.35% to $691000.0 in 2024, then dropped by 14.18% to $593000.0 in 2025, then soared by 102.36% to $1.2 million in 2026.
• Business Quant data shows IMDX's Other Non-Current Assets at $1.2 million in Q1 2026, $593000.0 in Q4 2025, and $672000.0 in Q3 2025.